Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK31679 in Patients With Metabolic Dysfunction Associated Steatohepatitis (MASH)
NCT07581951Phase 3Recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing HSK31679 dose with Placebo (2 arms). Primary endpoints: Resolution of Steatohepatitis Without Worsening of Fibrosis at 52 weeks, Improvement of Fibrosis >=1 Stage Without Worsening of Steatohepatitis at 52 weeks and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
HSK31679
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07581951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07581951.